Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Alopecia Areata | 30 | 2024 | 127 | 14.630 |
Why?
|
Acne Vulgaris | 25 | 2024 | 355 | 8.290 |
Why?
|
Dermatology | 38 | 2024 | 914 | 8.250 |
Why?
|
Pyoderma Gangrenosum | 19 | 2024 | 84 | 8.070 |
Why?
|
Dermatologic Agents | 18 | 2024 | 307 | 6.530 |
Why?
|
Cellulitis | 11 | 2024 | 207 | 5.760 |
Why?
|
Isotretinoin | 10 | 2024 | 131 | 4.690 |
Why?
|
Alopecia | 15 | 2024 | 414 | 4.090 |
Why?
|
Skin Diseases | 15 | 2024 | 1089 | 3.030 |
Why?
|
Pemphigoid, Bullous | 7 | 2024 | 114 | 2.330 |
Why?
|
Onychomycosis | 4 | 2018 | 50 | 2.240 |
Why?
|
Skin Neoplasms | 20 | 2023 | 5799 | 2.190 |
Why?
|
Stevens-Johnson Syndrome | 11 | 2024 | 244 | 2.000 |
Why?
|
Hidradenitis Suppurativa | 5 | 2024 | 173 | 1.930 |
Why?
|
Medicare Part D | 6 | 2022 | 354 | 1.830 |
Why?
|
Skin Diseases, Vesiculobullous | 4 | 2023 | 85 | 1.790 |
Why?
|
Foot Dermatoses | 3 | 2018 | 47 | 1.740 |
Why?
|
Eyebrows | 2 | 2024 | 35 | 1.640 |
Why?
|
Dermatitis, Atopic | 6 | 2024 | 716 | 1.530 |
Why?
|
Medicare Part B | 2 | 2024 | 117 | 1.460 |
Why?
|
Humans | 237 | 2024 | 760613 | 1.290 |
Why?
|
Psoriasis | 8 | 2024 | 940 | 1.290 |
Why?
|
Dietary Supplements | 6 | 2024 | 3392 | 1.280 |
Why?
|
Dapsone | 2 | 2018 | 56 | 1.260 |
Why?
|
Skin | 19 | 2024 | 4466 | 1.240 |
Why?
|
Phototherapy | 4 | 2024 | 368 | 1.220 |
Why?
|
Heterosexuality | 2 | 2020 | 294 | 1.190 |
Why?
|
United States | 68 | 2024 | 72448 | 1.190 |
Why?
|
Medicare | 11 | 2024 | 6785 | 1.180 |
Why?
|
Delphi Technique | 6 | 2024 | 829 | 1.170 |
Why?
|
Autoimmune Diseases | 4 | 2024 | 2250 | 1.160 |
Why?
|
Herpes Zoster | 2 | 2022 | 251 | 1.160 |
Why?
|
Eyelashes | 2 | 2024 | 19 | 1.130 |
Why?
|
Health Care Costs | 8 | 2023 | 3258 | 1.120 |
Why?
|
Sunburn | 3 | 2020 | 156 | 1.110 |
Why?
|
Drugs, Generic | 5 | 2020 | 448 | 1.100 |
Why?
|
Paraproteinemias | 2 | 2020 | 246 | 1.080 |
Why?
|
Decision Support Techniques | 4 | 2020 | 2001 | 1.070 |
Why?
|
Pemphigus | 2 | 2024 | 116 | 1.030 |
Why?
|
Drug Costs | 8 | 2022 | 1185 | 0.970 |
Why?
|
Severity of Illness Index | 9 | 2024 | 15840 | 0.970 |
Why?
|
Spironolactone | 2 | 2021 | 411 | 0.960 |
Why?
|
Adult | 87 | 2024 | 220007 | 0.940 |
Why?
|
Potassium | 2 | 2021 | 1313 | 0.930 |
Why?
|
International Classification of Diseases | 5 | 2024 | 894 | 0.930 |
Why?
|
Scalp | 5 | 2023 | 389 | 0.910 |
Why?
|
Drug Industry | 3 | 2019 | 789 | 0.910 |
Why?
|
Female | 111 | 2024 | 391246 | 0.890 |
Why?
|
Hair Removal | 1 | 2023 | 40 | 0.880 |
Why?
|
Retrospective Studies | 56 | 2024 | 80345 | 0.880 |
Why?
|
Melanosis | 5 | 2024 | 93 | 0.880 |
Why?
|
Cross-Sectional Studies | 29 | 2024 | 25941 | 0.880 |
Why?
|
Malnutrition | 2 | 2023 | 640 | 0.870 |
Why?
|
Referral and Consultation | 6 | 2020 | 3598 | 0.870 |
Why?
|
Administration, Topical | 8 | 2024 | 697 | 0.870 |
Why?
|
Melanoma | 6 | 2023 | 5697 | 0.860 |
Why?
|
Vasculitis, Leukocytoclastic, Cutaneous | 1 | 2023 | 42 | 0.860 |
Why?
|
Male | 97 | 2024 | 359718 | 0.850 |
Why?
|
Hyperpigmentation | 5 | 2024 | 117 | 0.820 |
Why?
|
Lupus Erythematosus, Cutaneous | 1 | 2023 | 73 | 0.820 |
Why?
|
Hair | 5 | 2024 | 497 | 0.810 |
Why?
|
Emergency Service, Hospital | 6 | 2019 | 7818 | 0.810 |
Why?
|
Acute Generalized Exanthematous Pustulosis | 1 | 2022 | 14 | 0.810 |
Why?
|
Hepatitis | 1 | 2024 | 231 | 0.790 |
Why?
|
Keratosis, Actinic | 2 | 2022 | 72 | 0.790 |
Why?
|
Fund Raising | 1 | 2022 | 49 | 0.780 |
Why?
|
Consent Forms | 1 | 2021 | 55 | 0.770 |
Why?
|
Chickenpox | 1 | 2022 | 97 | 0.770 |
Why?
|
Pancytopenia | 1 | 2022 | 101 | 0.760 |
Why?
|
Venous Thromboembolism | 3 | 2023 | 1864 | 0.740 |
Why?
|
Gender Identity | 4 | 2023 | 698 | 0.740 |
Why?
|
Skin Diseases, Infectious | 2 | 2019 | 77 | 0.730 |
Why?
|
Dermatitis, Irritant | 1 | 2020 | 18 | 0.720 |
Why?
|
Electronic Mail | 4 | 2015 | 213 | 0.720 |
Why?
|
Prevalence | 15 | 2024 | 15686 | 0.720 |
Why?
|
Minocycline | 4 | 2023 | 168 | 0.710 |
Why?
|
Dermatitis, Occupational | 1 | 2020 | 26 | 0.710 |
Why?
|
Necrobiotic Xanthogranuloma | 1 | 2020 | 10 | 0.710 |
Why?
|
Diagnostic Errors | 6 | 2022 | 1266 | 0.710 |
Why?
|
Consensus | 7 | 2024 | 3113 | 0.710 |
Why?
|
Equipment and Supplies, Hospital | 1 | 2020 | 59 | 0.710 |
Why?
|
Skin Diseases, Vascular | 1 | 2020 | 41 | 0.700 |
Why?
|
Sunbathing | 2 | 2020 | 65 | 0.700 |
Why?
|
Middle Aged | 64 | 2024 | 220359 | 0.700 |
Why?
|
Contraception | 2 | 2020 | 349 | 0.680 |
Why?
|
Private Practice | 1 | 2020 | 152 | 0.680 |
Why?
|
Health Expenditures | 8 | 2022 | 2362 | 0.680 |
Why?
|
Sex Reassignment Procedures | 1 | 2020 | 64 | 0.660 |
Why?
|
Patient Acceptance of Health Care | 3 | 2024 | 3164 | 0.640 |
Why?
|
Investments | 1 | 2020 | 148 | 0.640 |
Why?
|
Hospital Costs | 3 | 2020 | 976 | 0.640 |
Why?
|
Databases, Factual | 11 | 2024 | 8022 | 0.630 |
Why?
|
Appointments and Schedules | 3 | 2021 | 442 | 0.630 |
Why?
|
Internship and Residency | 8 | 2019 | 5870 | 0.630 |
Why?
|
Clinical Competence | 4 | 2019 | 4783 | 0.630 |
Why?
|
Models, Theoretical | 4 | 2019 | 3562 | 0.630 |
Why?
|
Thalidomide | 1 | 2024 | 884 | 0.620 |
Why?
|
Comorbidity | 7 | 2024 | 10553 | 0.620 |
Why?
|
Bandages | 1 | 2020 | 270 | 0.620 |
Why?
|
Cost Savings | 3 | 2019 | 920 | 0.620 |
Why?
|
Social Stigma | 2 | 2024 | 734 | 0.620 |
Why?
|
Young Adult | 32 | 2024 | 58748 | 0.620 |
Why?
|
Thermography | 1 | 2018 | 63 | 0.610 |
Why?
|
Scalp Dermatoses | 1 | 2018 | 44 | 0.610 |
Why?
|
Primary Health Care | 3 | 2020 | 4647 | 0.610 |
Why?
|
Cohort Effect | 1 | 2017 | 39 | 0.610 |
Why?
|
Insurance Claim Review | 2 | 2023 | 738 | 0.600 |
Why?
|
Clinical Trials as Topic | 3 | 2023 | 8055 | 0.600 |
Why?
|
Ointments | 1 | 2017 | 58 | 0.600 |
Why?
|
Behcet Syndrome | 1 | 2018 | 86 | 0.590 |
Why?
|
Adrenal Cortex Hormones | 5 | 2023 | 1869 | 0.580 |
Why?
|
Carcinoma, Basal Cell | 2 | 2022 | 559 | 0.570 |
Why?
|
Aged | 46 | 2024 | 169143 | 0.570 |
Why?
|
Acrodermatitis | 1 | 2016 | 15 | 0.570 |
Why?
|
Abnormalities, Drug-Induced | 1 | 2020 | 338 | 0.560 |
Why?
|
Treatment Refusal | 1 | 2020 | 430 | 0.560 |
Why?
|
Vitiligo | 3 | 2022 | 98 | 0.560 |
Why?
|
Microbiological Techniques | 1 | 2017 | 98 | 0.560 |
Why?
|
Patient Selection | 3 | 2023 | 4279 | 0.550 |
Why?
|
Physicians | 7 | 2022 | 4591 | 0.550 |
Why?
|
Patient Advocacy | 1 | 2019 | 358 | 0.550 |
Why?
|
Economic Competition | 1 | 2018 | 218 | 0.550 |
Why?
|
Clinical Coding | 1 | 2018 | 181 | 0.550 |
Why?
|
Hospitalization | 8 | 2024 | 10789 | 0.550 |
Why?
|
Immunoglobulins, Intravenous | 2 | 2018 | 664 | 0.540 |
Why?
|
Vasculitis | 1 | 2020 | 523 | 0.540 |
Why?
|
Waiting Lists | 1 | 2021 | 763 | 0.530 |
Why?
|
Homebound Persons | 1 | 2016 | 49 | 0.530 |
Why?
|
Professional Autonomy | 1 | 2017 | 171 | 0.530 |
Why?
|
Medical Staff, Hospital | 2 | 2019 | 600 | 0.520 |
Why?
|
Adolescent | 28 | 2024 | 87809 | 0.520 |
Why?
|
Patient Preference | 2 | 2020 | 922 | 0.520 |
Why?
|
Insurance Coverage | 3 | 2024 | 1939 | 0.520 |
Why?
|
Inflammatory Bowel Diseases | 5 | 2024 | 2421 | 0.510 |
Why?
|
Complementary Therapies | 1 | 2019 | 486 | 0.510 |
Why?
|
Patient Compliance | 2 | 2016 | 2688 | 0.510 |
Why?
|
Patient Discharge | 2 | 2020 | 3474 | 0.510 |
Why?
|
Counseling | 1 | 2023 | 1548 | 0.500 |
Why?
|
Patient Readmission | 2 | 2020 | 3322 | 0.500 |
Why?
|
Naphthalenes | 1 | 2016 | 198 | 0.490 |
Why?
|
Antipruritics | 1 | 2014 | 31 | 0.490 |
Why?
|
Mianserin | 1 | 2014 | 50 | 0.490 |
Why?
|
Immunologic Factors | 4 | 2024 | 1588 | 0.490 |
Why?
|
Financing, Personal | 1 | 2017 | 309 | 0.480 |
Why?
|
Herpes Simplex | 1 | 2018 | 478 | 0.480 |
Why?
|
Eosinophilia | 3 | 2024 | 559 | 0.480 |
Why?
|
Adjuvants, Immunologic | 3 | 2022 | 1039 | 0.470 |
Why?
|
Sarcoidosis | 2 | 2024 | 520 | 0.470 |
Why?
|
Curriculum | 3 | 2019 | 3718 | 0.470 |
Why?
|
Sexual Behavior | 3 | 2023 | 2086 | 0.470 |
Why?
|
United States Food and Drug Administration | 3 | 2020 | 1677 | 0.470 |
Why?
|
Risk-Taking | 1 | 2020 | 998 | 0.460 |
Why?
|
Tattooing | 1 | 2014 | 57 | 0.460 |
Why?
|
Biopsy | 9 | 2023 | 6771 | 0.460 |
Why?
|
Conflict of Interest | 1 | 2019 | 549 | 0.460 |
Why?
|
Physician Assistants | 1 | 2016 | 188 | 0.450 |
Why?
|
Congresses as Topic | 1 | 2019 | 805 | 0.450 |
Why?
|
Technology | 1 | 2016 | 291 | 0.450 |
Why?
|
Patient Education as Topic | 3 | 2024 | 2315 | 0.450 |
Why?
|
Fee-for-Service Plans | 2 | 2018 | 705 | 0.440 |
Why?
|
Patient Admission | 2 | 2020 | 1385 | 0.440 |
Why?
|
Postoperative Hemorrhage | 1 | 2017 | 422 | 0.440 |
Why?
|
Acetaminophen | 1 | 2017 | 553 | 0.430 |
Why?
|
World Health Organization | 1 | 2019 | 1314 | 0.430 |
Why?
|
Medicaid | 3 | 2024 | 2815 | 0.430 |
Why?
|
Hyperkalemia | 1 | 2015 | 231 | 0.430 |
Why?
|
Nurse Practitioners | 1 | 2016 | 268 | 0.430 |
Why?
|
Drug Prescriptions | 3 | 2024 | 1673 | 0.420 |
Why?
|
Glucocorticoids | 3 | 2022 | 2145 | 0.410 |
Why?
|
Arthritis | 1 | 2018 | 666 | 0.410 |
Why?
|
Skin Ulcer | 2 | 2024 | 129 | 0.410 |
Why?
|
Zinc | 1 | 2016 | 689 | 0.410 |
Why?
|
Decision Making | 5 | 2024 | 3925 | 0.410 |
Why?
|
Cohort Studies | 20 | 2023 | 41337 | 0.400 |
Why?
|
Internet | 5 | 2015 | 3078 | 0.400 |
Why?
|
Lupus Erythematosus, Systemic | 2 | 2023 | 2160 | 0.400 |
Why?
|
Telemedicine | 4 | 2022 | 3018 | 0.400 |
Why?
|
Medical Informatics | 2 | 2020 | 733 | 0.390 |
Why?
|
Physician-Patient Relations | 6 | 2020 | 3242 | 0.380 |
Why?
|
Insurance, Health | 2 | 2021 | 2501 | 0.380 |
Why?
|
Health Services Accessibility | 6 | 2024 | 5397 | 0.380 |
Why?
|
Analgesics, Opioid | 2 | 2018 | 3763 | 0.380 |
Why?
|
Pruritus | 1 | 2014 | 377 | 0.380 |
Why?
|
Point-of-Care Systems | 1 | 2020 | 1204 | 0.380 |
Why?
|
Ultraviolet Therapy | 2 | 2024 | 84 | 0.370 |
Why?
|
Anti-Infective Agents | 1 | 2018 | 981 | 0.370 |
Why?
|
Education, Medical, Graduate | 4 | 2020 | 2363 | 0.370 |
Why?
|
Tuberculosis | 1 | 2024 | 2001 | 0.370 |
Why?
|
Ethics, Professional | 1 | 2011 | 100 | 0.370 |
Why?
|
Anti-Bacterial Agents | 9 | 2023 | 7408 | 0.360 |
Why?
|
Triazoles | 1 | 2016 | 904 | 0.360 |
Why?
|
Electronic Health Records | 4 | 2024 | 4775 | 0.350 |
Why?
|
Travel | 1 | 2016 | 785 | 0.350 |
Why?
|
Tretinoin | 2 | 2024 | 519 | 0.350 |
Why?
|
Continuity of Patient Care | 1 | 2017 | 1066 | 0.340 |
Why?
|
Incidence | 11 | 2024 | 21391 | 0.340 |
Why?
|
Mental Disorders | 3 | 2024 | 6796 | 0.340 |
Why?
|
Confidentiality | 1 | 2014 | 609 | 0.340 |
Why?
|
Diagnostic Imaging | 2 | 2021 | 3527 | 0.340 |
Why?
|
Perception | 1 | 2016 | 1195 | 0.340 |
Why?
|
Online Systems | 1 | 2010 | 181 | 0.330 |
Why?
|
Artificial Intelligence | 2 | 2023 | 2557 | 0.330 |
Why?
|
Costs and Cost Analysis | 3 | 2022 | 1677 | 0.330 |
Why?
|
Thrombocytopenia | 1 | 2017 | 1174 | 0.330 |
Why?
|
Career Choice | 1 | 2015 | 754 | 0.330 |
Why?
|
Behavioral Risk Factor Surveillance System | 2 | 2020 | 208 | 0.320 |
Why?
|
Internal Medicine | 2 | 2015 | 1048 | 0.320 |
Why?
|
Delivery of Health Care | 5 | 2022 | 5325 | 0.320 |
Why?
|
Time Factors | 12 | 2021 | 40139 | 0.310 |
Why?
|
Antifungal Agents | 3 | 2018 | 749 | 0.310 |
Why?
|
Gastric Bypass | 1 | 2016 | 826 | 0.300 |
Why?
|
Cost-Benefit Analysis | 3 | 2024 | 5508 | 0.290 |
Why?
|
Monitoring, Physiologic | 1 | 2015 | 1784 | 0.290 |
Why?
|
Private Sector | 2 | 2021 | 397 | 0.290 |
Why?
|
Observer Variation | 4 | 2021 | 2601 | 0.290 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 1 | 2017 | 2282 | 0.290 |
Why?
|
Alanine Transaminase | 2 | 2020 | 607 | 0.290 |
Why?
|
Remote Consultation | 2 | 2020 | 234 | 0.290 |
Why?
|
Carcinoma, Ductal, Breast | 1 | 2014 | 1096 | 0.290 |
Why?
|
Wound Healing | 1 | 2018 | 2788 | 0.280 |
Why?
|
Disease Management | 1 | 2017 | 2514 | 0.280 |
Why?
|
Societies, Medical | 1 | 2019 | 3905 | 0.280 |
Why?
|
Bacteria | 1 | 2017 | 2199 | 0.270 |
Why?
|
Ambulatory Care | 1 | 2017 | 2782 | 0.270 |
Why?
|
Mohs Surgery | 2 | 2020 | 221 | 0.260 |
Why?
|
Pandemics | 3 | 2020 | 8623 | 0.260 |
Why?
|
Surgical Procedures, Operative | 1 | 2017 | 1913 | 0.260 |
Why?
|
Sex Factors | 4 | 2020 | 10546 | 0.250 |
Why?
|
Patient Care | 2 | 2022 | 624 | 0.250 |
Why?
|
Communication | 2 | 2023 | 3849 | 0.250 |
Why?
|
Privacy | 2 | 2022 | 233 | 0.250 |
Why?
|
Comprehension | 2 | 2021 | 617 | 0.250 |
Why?
|
Mass Screening | 2 | 2020 | 5422 | 0.250 |
Why?
|
Child | 15 | 2024 | 79799 | 0.240 |
Why?
|
Diagnosis, Differential | 8 | 2019 | 12968 | 0.240 |
Why?
|
Vaccines | 2 | 2024 | 832 | 0.240 |
Why?
|
Quality of Life | 9 | 2024 | 13308 | 0.240 |
Why?
|
Risk Factors | 15 | 2024 | 74333 | 0.240 |
Why?
|
Postoperative Complications | 2 | 2017 | 15679 | 0.240 |
Why?
|
Epidermolysis Bullosa | 1 | 2024 | 29 | 0.230 |
Why?
|
Physical Examination | 4 | 2022 | 1244 | 0.230 |
Why?
|
Epidermolysis Bullosa Dystrophica | 1 | 2024 | 28 | 0.230 |
Why?
|
Blister | 2 | 2023 | 87 | 0.220 |
Why?
|
Islam | 1 | 2024 | 71 | 0.220 |
Why?
|
Cortodoxone | 1 | 2023 | 17 | 0.220 |
Why?
|
Nonprescription Drugs | 1 | 2024 | 118 | 0.220 |
Why?
|
Triglycerides | 2 | 2022 | 2476 | 0.220 |
Why?
|
Treatment Outcome | 11 | 2023 | 64981 | 0.220 |
Why?
|
Hypersensitivity, Delayed | 1 | 2024 | 490 | 0.220 |
Why?
|
Predictive Value of Tests | 5 | 2024 | 15286 | 0.210 |
Why?
|
Stereotyping | 2 | 2024 | 239 | 0.210 |
Why?
|
Azetidines | 1 | 2024 | 141 | 0.210 |
Why?
|
Leg | 2 | 2018 | 1091 | 0.210 |
Why?
|
Methotrexate | 3 | 2024 | 1718 | 0.210 |
Why?
|
Age Factors | 5 | 2020 | 18413 | 0.200 |
Why?
|
Propionates | 1 | 2023 | 182 | 0.200 |
Why?
|
Conjunctivitis, Bacterial | 1 | 2022 | 22 | 0.200 |
Why?
|
Registries | 2 | 2018 | 8458 | 0.200 |
Why?
|
Rosacea | 1 | 2022 | 59 | 0.200 |
Why?
|
Aged, 80 and over | 9 | 2020 | 58980 | 0.200 |
Why?
|
Lichen Planus | 1 | 2022 | 71 | 0.200 |
Why?
|
Insurance Carriers | 1 | 2023 | 156 | 0.200 |
Why?
|
Contraceptive Agents, Female | 2 | 2020 | 118 | 0.200 |
Why?
|
Length of Stay | 3 | 2020 | 6476 | 0.200 |
Why?
|
Administration, Oral | 3 | 2023 | 4035 | 0.200 |
Why?
|
Stress Disorders, Post-Traumatic | 1 | 2019 | 4555 | 0.190 |
Why?
|
Retinoids | 1 | 2022 | 98 | 0.190 |
Why?
|
Hospital Mortality | 3 | 2020 | 5418 | 0.190 |
Why?
|
Drug Eruptions | 2 | 2024 | 335 | 0.190 |
Why?
|
Prospective Studies | 8 | 2020 | 54306 | 0.190 |
Why?
|
Herpesvirus 3, Human | 1 | 2022 | 158 | 0.190 |
Why?
|
Conjunctivitis, Allergic | 1 | 2022 | 123 | 0.190 |
Why?
|
Narration | 1 | 2023 | 219 | 0.180 |
Why?
|
Conjunctivitis | 1 | 2022 | 155 | 0.180 |
Why?
|
Desmoplakins | 1 | 2020 | 62 | 0.180 |
Why?
|
Soft Tissue Infections | 1 | 2022 | 168 | 0.180 |
Why?
|
Photography | 2 | 2020 | 530 | 0.180 |
Why?
|
Purines | 1 | 2024 | 605 | 0.180 |
Why?
|
Colitis, Ulcerative | 2 | 2023 | 1919 | 0.180 |
Why?
|
Case-Control Studies | 7 | 2024 | 22052 | 0.180 |
Why?
|
Early Termination of Clinical Trials | 1 | 2020 | 71 | 0.180 |
Why?
|
Controlled Clinical Trials as Topic | 1 | 2021 | 186 | 0.180 |
Why?
|
Sexual Abstinence | 1 | 2020 | 16 | 0.180 |
Why?
|
Eczema | 1 | 2023 | 245 | 0.180 |
Why?
|
Contraceptive Devices, Female | 1 | 2020 | 40 | 0.170 |
Why?
|
Prescriptions | 1 | 2022 | 388 | 0.170 |
Why?
|
Eligibility Determination | 1 | 2023 | 419 | 0.170 |
Why?
|
Immunoglobulin A | 1 | 2023 | 978 | 0.170 |
Why?
|
Probiotics | 1 | 2023 | 377 | 0.170 |
Why?
|
Disclosure | 2 | 2019 | 738 | 0.170 |
Why?
|
Algorithms | 5 | 2024 | 13982 | 0.170 |
Why?
|
Evidence-Based Medicine | 3 | 2020 | 3696 | 0.170 |
Why?
|
Arthritis, Psoriatic | 1 | 2022 | 219 | 0.170 |
Why?
|
Necrobiosis Lipoidica | 1 | 2019 | 14 | 0.170 |
Why?
|
Chronic Disease | 5 | 2022 | 9288 | 0.170 |
Why?
|
Contraceptives, Oral, Combined | 1 | 2020 | 116 | 0.170 |
Why?
|
Lasers | 1 | 2023 | 952 | 0.170 |
Why?
|
Cyclosporine | 2 | 2022 | 777 | 0.170 |
Why?
|
Arrhythmogenic Right Ventricular Dysplasia | 1 | 2020 | 162 | 0.160 |
Why?
|
Anticoagulants | 1 | 2015 | 4897 | 0.160 |
Why?
|
Sulfamethoxazole | 1 | 2018 | 53 | 0.160 |
Why?
|
Drugs, Essential | 1 | 2019 | 70 | 0.160 |
Why?
|
Vitamins | 2 | 2024 | 1634 | 0.160 |
Why?
|
Steroids | 2 | 2022 | 928 | 0.160 |
Why?
|
Specialty Boards | 1 | 2020 | 235 | 0.160 |
Why?
|
Withholding Treatment | 2 | 2020 | 613 | 0.160 |
Why?
|
Trimethoprim | 1 | 2018 | 84 | 0.160 |
Why?
|
Hospitals, University | 1 | 2020 | 568 | 0.160 |
Why?
|
Massachusetts | 4 | 2020 | 8803 | 0.160 |
Why?
|
Reproducibility of Results | 4 | 2022 | 20080 | 0.160 |
Why?
|
Liver Function Tests | 1 | 2020 | 524 | 0.150 |
Why?
|
Neoplasms | 4 | 2022 | 22075 | 0.150 |
Why?
|
Skin Temperature | 1 | 2018 | 96 | 0.150 |
Why?
|
Personal Satisfaction | 1 | 2022 | 643 | 0.150 |
Why?
|
Condoms | 1 | 2020 | 315 | 0.150 |
Why?
|
Genes, Dominant | 1 | 2020 | 863 | 0.150 |
Why?
|
Qualitative Research | 2 | 2020 | 2963 | 0.150 |
Why?
|
North America | 1 | 2021 | 1284 | 0.150 |
Why?
|
Cancer Care Facilities | 1 | 2020 | 424 | 0.150 |
Why?
|
Review Literature as Topic | 1 | 2019 | 350 | 0.150 |
Why?
|
Transaminases | 1 | 2018 | 196 | 0.140 |
Why?
|
Platelet Count | 1 | 2020 | 777 | 0.140 |
Why?
|
Early Detection of Cancer | 3 | 2020 | 3202 | 0.140 |
Why?
|
Off-Label Use | 1 | 2019 | 184 | 0.140 |
Why?
|
Certification | 1 | 2020 | 421 | 0.140 |
Why?
|
Herpes Zoster Vaccine | 1 | 2017 | 49 | 0.140 |
Why?
|
Hospitals, Urban | 1 | 2019 | 499 | 0.140 |
Why?
|
Government Programs | 1 | 2019 | 280 | 0.140 |
Why?
|
Spondylitis, Ankylosing | 1 | 2018 | 152 | 0.140 |
Why?
|
Computer Systems | 1 | 2018 | 470 | 0.140 |
Why?
|
Periodic Acid-Schiff Reaction | 1 | 2016 | 16 | 0.140 |
Why?
|
Polycythemia Vera | 1 | 2018 | 160 | 0.140 |
Why?
|
Genital Diseases, Female | 1 | 2017 | 191 | 0.140 |
Why?
|
Hydroxides | 1 | 2016 | 46 | 0.130 |
Why?
|
Ultraviolet Rays | 2 | 2020 | 1078 | 0.130 |
Why?
|
Boston | 4 | 2017 | 9278 | 0.130 |
Why?
|
Potassium Compounds | 1 | 2016 | 42 | 0.130 |
Why?
|
Health Surveys | 2 | 2024 | 4063 | 0.130 |
Why?
|
Hospital Charges | 1 | 2018 | 359 | 0.130 |
Why?
|
Leukocyte Count | 1 | 2020 | 1599 | 0.130 |
Why?
|
Cost of Illness | 2 | 2022 | 1940 | 0.130 |
Why?
|
Blastomyces | 1 | 2015 | 10 | 0.130 |
Why?
|
Pilot Projects | 2 | 2020 | 8556 | 0.130 |
Why?
|
Blastomycosis | 1 | 2015 | 14 | 0.130 |
Why?
|
Outpatients | 1 | 2024 | 1607 | 0.130 |
Why?
|
Comparative Effectiveness Research | 1 | 2021 | 718 | 0.130 |
Why?
|
Parenteral Nutrition, Total | 1 | 2016 | 303 | 0.130 |
Why?
|
Debridement | 1 | 2018 | 492 | 0.130 |
Why?
|
Leukocytosis | 1 | 2017 | 251 | 0.130 |
Why?
|
Adverse Drug Reaction Reporting Systems | 1 | 2019 | 488 | 0.130 |
Why?
|
Microcirculation | 1 | 2020 | 1278 | 0.130 |
Why?
|
Wound Infection | 1 | 2018 | 244 | 0.130 |
Why?
|
Diet | 2 | 2024 | 8010 | 0.130 |
Why?
|
Breast Neoplasms | 2 | 2022 | 21029 | 0.120 |
Why?
|
Trace Elements | 1 | 2016 | 196 | 0.120 |
Why?
|
Informed Consent | 1 | 2021 | 1005 | 0.120 |
Why?
|
Myocardial Infarction | 1 | 2016 | 11890 | 0.120 |
Why?
|
Drug Monitoring | 1 | 2021 | 965 | 0.120 |
Why?
|
Autoantibodies | 1 | 2023 | 2119 | 0.120 |
Why?
|
Sensitivity and Specificity | 3 | 2022 | 14661 | 0.120 |
Why?
|
Tachycardia | 1 | 2017 | 603 | 0.120 |
Why?
|
Histamine Antagonists | 1 | 2014 | 90 | 0.120 |
Why?
|
Odds Ratio | 2 | 2017 | 9716 | 0.120 |
Why?
|
Health Literacy | 1 | 2020 | 440 | 0.120 |
Why?
|
Serotonin Antagonists | 1 | 2014 | 144 | 0.120 |
Why?
|
Medical Records | 1 | 2020 | 1407 | 0.120 |
Why?
|
Analgesics, Non-Narcotic | 1 | 2017 | 370 | 0.120 |
Why?
|
Face | 1 | 2020 | 1017 | 0.120 |
Why?
|
Emotions | 2 | 2023 | 2734 | 0.120 |
Why?
|
Decision Trees | 1 | 2016 | 506 | 0.110 |
Why?
|
Area Under Curve | 1 | 2018 | 1635 | 0.110 |
Why?
|
Diagnostic Tests, Routine | 1 | 2020 | 786 | 0.110 |
Why?
|
Sulfonamides | 1 | 2024 | 1977 | 0.110 |
Why?
|
Epidemiologic Studies | 1 | 2017 | 670 | 0.110 |
Why?
|
Attitude of Health Personnel | 3 | 2019 | 3865 | 0.110 |
Why?
|
Androgen Antagonists | 1 | 2023 | 1442 | 0.110 |
Why?
|
Video Recording | 1 | 2019 | 955 | 0.110 |
Why?
|
Cost Sharing | 1 | 2017 | 410 | 0.110 |
Why?
|
Stroke | 1 | 2016 | 9952 | 0.110 |
Why?
|
Mastectomy | 1 | 2022 | 1832 | 0.110 |
Why?
|
Commerce | 1 | 2019 | 605 | 0.110 |
Why?
|
Central Nervous System Diseases | 1 | 2018 | 521 | 0.110 |
Why?
|
Psychometrics | 1 | 2023 | 3051 | 0.110 |
Why?
|
Statistics, Nonparametric | 1 | 2019 | 2852 | 0.110 |
Why?
|
Epidemiologic Methods | 1 | 2018 | 1343 | 0.110 |
Why?
|
Secondary Prevention | 1 | 2020 | 1548 | 0.110 |
Why?
|
Biological Products | 1 | 2022 | 916 | 0.110 |
Why?
|
Documentation | 1 | 2019 | 893 | 0.110 |
Why?
|
Alcoholism | 1 | 2024 | 1961 | 0.110 |
Why?
|
Health Records, Personal | 1 | 2014 | 127 | 0.110 |
Why?
|
Unnecessary Procedures | 1 | 2016 | 413 | 0.100 |
Why?
|
Antidepressive Agents, Tricyclic | 1 | 2014 | 432 | 0.100 |
Why?
|
Interviews as Topic | 1 | 2020 | 2659 | 0.100 |
Why?
|
Tetracycline | 2 | 2023 | 220 | 0.100 |
Why?
|
Tumor Necrosis Factor-alpha | 1 | 2024 | 4356 | 0.100 |
Why?
|
Prescription Drugs | 1 | 2020 | 630 | 0.100 |
Why?
|
Canada | 1 | 2018 | 2126 | 0.100 |
Why?
|
Diabetes Mellitus | 2 | 2022 | 5890 | 0.100 |
Why?
|
Randomized Controlled Trials as Topic | 3 | 2024 | 10343 | 0.100 |
Why?
|
Reimbursement Mechanisms | 1 | 2018 | 664 | 0.100 |
Why?
|
Primary Prevention | 1 | 2020 | 1207 | 0.100 |
Why?
|
Risk Assessment | 3 | 2018 | 24102 | 0.100 |
Why?
|
Radiography | 2 | 2020 | 6965 | 0.100 |
Why?
|
Nose | 1 | 2015 | 519 | 0.100 |
Why?
|
Health Care Surveys | 1 | 2019 | 2435 | 0.100 |
Why?
|
Needs Assessment | 1 | 2018 | 1139 | 0.100 |
Why?
|
Educational Technology | 1 | 2011 | 59 | 0.100 |
Why?
|
Income | 1 | 2020 | 1875 | 0.100 |
Why?
|
Cholesterol | 1 | 2020 | 2924 | 0.090 |
Why?
|
Disabled Persons | 1 | 2020 | 1223 | 0.090 |
Why?
|
ROC Curve | 1 | 2018 | 3568 | 0.090 |
Why?
|
Emergencies | 1 | 2017 | 1210 | 0.090 |
Why?
|
Drug Interactions | 1 | 2015 | 1428 | 0.090 |
Why?
|
Guideline Adherence | 1 | 2020 | 2283 | 0.090 |
Why?
|
Pregnancy | 3 | 2022 | 29746 | 0.090 |
Why?
|
Bacteremia | 1 | 2017 | 980 | 0.090 |
Why?
|
Crohn Disease | 1 | 2022 | 2275 | 0.080 |
Why?
|
Health Resources | 1 | 2016 | 935 | 0.080 |
Why?
|
Gastrointestinal Diseases | 1 | 2018 | 1189 | 0.080 |
Why?
|
Hospital Information Systems | 1 | 2011 | 394 | 0.080 |
Why?
|
Pleurisy | 1 | 2009 | 54 | 0.080 |
Why?
|
Search Engine | 1 | 2010 | 140 | 0.080 |
Why?
|
Attitude to Health | 1 | 2017 | 2029 | 0.080 |
Why?
|
Self Report | 1 | 2020 | 3711 | 0.080 |
Why?
|
Propensity Score | 1 | 2016 | 1926 | 0.080 |
Why?
|
Longitudinal Studies | 1 | 2024 | 14494 | 0.080 |
Why?
|
Decision Support Systems, Clinical | 1 | 2017 | 1164 | 0.070 |
Why?
|
Biomedical Research | 1 | 2023 | 3426 | 0.070 |
Why?
|
Drug Therapy, Combination | 1 | 2017 | 6498 | 0.070 |
Why?
|
Risk | 2 | 2016 | 9632 | 0.070 |
Why?
|
Head | 2 | 2023 | 922 | 0.070 |
Why?
|
Hospitals | 1 | 2020 | 3928 | 0.070 |
Why?
|
Health Personnel | 1 | 2020 | 3310 | 0.070 |
Why?
|
Mental Health | 1 | 2020 | 3213 | 0.070 |
Why?
|
Head and Neck Neoplasms | 1 | 2020 | 2882 | 0.070 |
Why?
|
Pleural Effusion | 1 | 2009 | 343 | 0.070 |
Why?
|
Stress, Psychological | 1 | 2021 | 4446 | 0.060 |
Why?
|
Fractures, Bone | 1 | 2018 | 2041 | 0.060 |
Why?
|
Phenotype | 1 | 2023 | 16548 | 0.060 |
Why?
|
Asthma | 2 | 2022 | 6172 | 0.060 |
Why?
|
Recurrence | 1 | 2017 | 8483 | 0.060 |
Why?
|
Disease Progression | 2 | 2023 | 13505 | 0.060 |
Why?
|
Keratolytic Agents | 1 | 2024 | 34 | 0.060 |
Why?
|
User-Computer Interface | 2 | 2011 | 1403 | 0.060 |
Why?
|
Physicians, Women | 1 | 2010 | 495 | 0.060 |
Why?
|
Protein Kinase Inhibitors | 1 | 2020 | 5640 | 0.060 |
Why?
|
Carcinoma, Merkel Cell | 1 | 2008 | 321 | 0.060 |
Why?
|
Organizational Innovation | 1 | 2006 | 536 | 0.050 |
Why?
|
Information Dissemination | 1 | 2011 | 1131 | 0.050 |
Why?
|
Anthralin | 1 | 2022 | 5 | 0.050 |
Why?
|
Pain | 1 | 2018 | 5066 | 0.050 |
Why?
|
Minoxidil | 1 | 2022 | 34 | 0.050 |
Why?
|
Arthritis, Rheumatoid | 1 | 2018 | 3763 | 0.050 |
Why?
|
Multiple Myeloma | 1 | 2020 | 5131 | 0.050 |
Why?
|
Doxycycline | 1 | 2023 | 341 | 0.050 |
Why?
|
Biological Therapy | 1 | 2022 | 139 | 0.050 |
Why?
|
Colorectal Neoplasms | 1 | 2020 | 6853 | 0.050 |
Why?
|
Vaccination | 2 | 2023 | 3359 | 0.040 |
Why?
|
Current Procedural Terminology | 1 | 2021 | 90 | 0.040 |
Why?
|
Intrauterine Devices, Medicated | 1 | 2020 | 26 | 0.040 |
Why?
|
Intrauterine Devices, Copper | 1 | 2020 | 30 | 0.040 |
Why?
|
Levonorgestrel | 1 | 2020 | 74 | 0.040 |
Why?
|
Antineoplastic Agents | 2 | 2020 | 13627 | 0.040 |
Why?
|
Autopsy | 1 | 2024 | 1007 | 0.040 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2024 | 861 | 0.040 |
Why?
|
Protective Clothing | 1 | 2020 | 103 | 0.040 |
Why?
|
Prognosis | 4 | 2023 | 29661 | 0.040 |
Why?
|
Inpatients | 2 | 2024 | 2580 | 0.040 |
Why?
|
Hospitals, Special | 1 | 2019 | 90 | 0.040 |
Why?
|
Sunscreening Agents | 1 | 2020 | 139 | 0.040 |
Why?
|
Postoperative Period | 1 | 2024 | 1818 | 0.040 |
Why?
|
Diagnostic Techniques and Procedures | 1 | 2021 | 220 | 0.040 |
Why?
|
Mouth Mucosa | 1 | 2021 | 426 | 0.040 |
Why?
|
Immunocompromised Host | 2 | 2017 | 857 | 0.040 |
Why?
|
Seasons | 1 | 2023 | 1522 | 0.040 |
Why?
|
T-Lymphocytes, Cytotoxic | 1 | 2024 | 1765 | 0.040 |
Why?
|
Neck | 1 | 2022 | 731 | 0.040 |
Why?
|
Lung | 1 | 2015 | 9994 | 0.030 |
Why?
|
Obesity | 1 | 2019 | 12919 | 0.030 |
Why?
|
Efficiency | 1 | 2019 | 477 | 0.030 |
Why?
|
Hospitalists | 1 | 2020 | 295 | 0.030 |
Why?
|
Fever | 1 | 2023 | 1617 | 0.030 |
Why?
|
Thyroid Diseases | 1 | 2019 | 386 | 0.030 |
Why?
|
Antigens, Fungal | 1 | 2015 | 69 | 0.030 |
Why?
|
Fibrosis | 1 | 2022 | 2042 | 0.030 |
Why?
|
Hypothermia, Induced | 1 | 2020 | 758 | 0.030 |
Why?
|
Efficiency, Organizational | 1 | 2019 | 697 | 0.030 |
Why?
|
Education, Medical | 1 | 2006 | 1727 | 0.030 |
Why?
|
Psychiatry | 1 | 2006 | 1689 | 0.030 |
Why?
|
Immunosuppressive Agents | 2 | 2022 | 4167 | 0.030 |
Why?
|
Sex Distribution | 1 | 2019 | 2294 | 0.030 |
Why?
|
Models, Economic | 1 | 2018 | 719 | 0.030 |
Why?
|
Pyrazoles | 1 | 2024 | 1999 | 0.030 |
Why?
|
Anticonvulsants | 1 | 2023 | 1879 | 0.030 |
Why?
|
Patient Participation | 1 | 2022 | 1439 | 0.030 |
Why?
|
Nose Neoplasms | 1 | 2015 | 249 | 0.030 |
Why?
|
Disease Outbreaks | 1 | 2022 | 1758 | 0.030 |
Why?
|
Age Distribution | 1 | 2019 | 2893 | 0.030 |
Why?
|
Research | 1 | 2021 | 1974 | 0.030 |
Why?
|
Morbidity | 1 | 2018 | 1765 | 0.030 |
Why?
|
Delivery of Health Care, Integrated | 1 | 2020 | 936 | 0.030 |
Why?
|
Medicine | 1 | 2020 | 943 | 0.030 |
Why?
|
Fellowships and Scholarships | 1 | 2020 | 1116 | 0.020 |
Why?
|
Information Management | 1 | 2011 | 100 | 0.020 |
Why?
|
Dyslipidemias | 1 | 2019 | 895 | 0.020 |
Why?
|
Delayed Diagnosis | 1 | 2015 | 464 | 0.020 |
Why?
|
Faculty, Medical | 1 | 2019 | 1192 | 0.020 |
Why?
|
Acute Disease | 1 | 2022 | 7268 | 0.020 |
Why?
|
CD8-Positive T-Lymphocytes | 1 | 2024 | 4550 | 0.020 |
Why?
|
Computer Communication Networks | 1 | 2011 | 294 | 0.020 |
Why?
|
Feasibility Studies | 1 | 2020 | 5201 | 0.020 |
Why?
|
Medical Oncology | 1 | 2020 | 2313 | 0.020 |
Why?
|
Double-Blind Method | 1 | 2023 | 12427 | 0.020 |
Why?
|
Healthcare Disparities | 1 | 2024 | 3386 | 0.020 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2023 | 3985 | 0.020 |
Why?
|
Patients | 1 | 2014 | 906 | 0.020 |
Why?
|
Pleura | 1 | 2009 | 244 | 0.020 |
Why?
|
Dyspnea | 1 | 2015 | 1353 | 0.020 |
Why?
|
Mycophenolic Acid | 1 | 2009 | 343 | 0.020 |
Why?
|
Information Storage and Retrieval | 1 | 2011 | 822 | 0.020 |
Why?
|
Venous Thrombosis | 1 | 2015 | 1300 | 0.020 |
Why?
|
Combined Modality Therapy | 1 | 2017 | 8552 | 0.020 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2018 | 10826 | 0.020 |
Why?
|
Lupus Nephritis | 1 | 2009 | 318 | 0.020 |
Why?
|
Critical Care | 1 | 2018 | 2699 | 0.020 |
Why?
|
Survival Analysis | 1 | 2018 | 10185 | 0.020 |
Why?
|
Academic Medical Centers | 1 | 2014 | 2754 | 0.010 |
Why?
|
Survival Rate | 1 | 2018 | 12810 | 0.010 |
Why?
|
Program Evaluation | 1 | 2011 | 2493 | 0.010 |
Why?
|
Practice Guidelines as Topic | 1 | 2020 | 7475 | 0.010 |
Why?
|
Early Diagnosis | 1 | 2008 | 1180 | 0.010 |
Why?
|
Pulmonary Embolism | 1 | 2015 | 2543 | 0.010 |
Why?
|
Antibodies, Monoclonal | 1 | 2017 | 9185 | 0.010 |
Why?
|
Patient Satisfaction | 1 | 2013 | 3448 | 0.010 |
Why?
|
Cell Division | 1 | 2008 | 4463 | 0.010 |
Why?
|
Inflammation | 1 | 2020 | 10755 | 0.010 |
Why?
|
Carcinoma, Squamous Cell | 1 | 2015 | 4024 | 0.010 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 1 | 2020 | 11713 | 0.010 |
Why?
|
Follow-Up Studies | 1 | 2020 | 39262 | 0.010 |
Why?
|
Teaching | 1 | 2006 | 1169 | 0.010 |
Why?
|
Hypertension | 1 | 2019 | 8595 | 0.010 |
Why?
|
Quality of Health Care | 1 | 2013 | 4360 | 0.010 |
Why?
|
Mice | 1 | 2024 | 81209 | 0.010 |
Why?
|
Mutation | 1 | 2020 | 29957 | 0.010 |
Why?
|
Infant | 1 | 2018 | 36053 | 0.010 |
Why?
|
Child, Preschool | 1 | 2018 | 42056 | 0.010 |
Why?
|
Kidney | 1 | 2009 | 7064 | 0.010 |
Why?
|
Environmental Exposure | 1 | 2008 | 4412 | 0.010 |
Why?
|
Animals | 1 | 2024 | 167960 | 0.010 |
Why?
|